Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
21 Mar, 2023 (Tuesday)

            
GREENTOWN MGMT(9979)
Analysis:
GREENTOWN MANAGEMENT (9979) is primarily engaged in the provision of project management services. In 2022, China`s real estate market faced pressure in general, and state-owned enterprises, central enterprises and local urban investment companies have become the main land acquirers. Land acquisition projects of urban investment companies in search for professional development services has become the major trend. China has begun to accelerate the construction of affordable housing for lowincome and middle-income groups and young people, and the government has started to promote its project management model nationwide. Under the policy of “ensure the delivery of properties”, financial institutions accelerated the development and construction of non-performing projects, and the bailout market was large. Therefore, investment in China`s real estate market has shown a decentralization trend, with more and more business opportunities from clients such as the government, state-owned enterprises, local urban investment companies, and financial institutions, bringing about a new round of development opportunities for property management. For the financial year ended 31 December 2022, revenue from continuing operations of the Group reached RMB2,656.0 million, representing an increase of 18.4% as compared to the corresponding period of 2021. The net profit attributable to shareholders of the Company was RMB744.5 million, representing an increase of 31.7%. The comprehensive gross profit margin rate reached 52.3%, an increase of 5.9 percentage points over 46.4% in the same period last year. The net cash flow from operating activities of the Company reached RMB724.7 million and the Company had no liabilities and sufficient cash flow. (I do not hold the above stock)
Strategy:
Buy-in Price: $7.10, Target Price: $8.00, Cut Loss Price: $6.60


IMAX CHINA(1970)
Analysis:
IMAX CHINA is the exclusive licensee of the IMAX brand and the only commercial platform for the release of IMAX films for Greater China`s leading entertainment technology company, theater network, sales and maintenance business. According to Chinese media reports, the mainland`s box office in 2023 has exceeded RMB 15 billion, which is about two months earlier than in 2022. The data shows that after the relaxation of China`s epidemic prevention policy, mainland citizens` demand for film and television entertainment has increased significantly. Under this situation, Meng Danqing, CEO of IMAX China, said in an interview that “Fast and Furious 10” and “Transformers 7” are expected to be released this year. From May to the end of the year, there will be a new IMAX film to meet the audience every week. Besides, the film schedule in China is much looser now. For example, the films can be scheduled to release in July. Distributors can leave enough time for the film to warm up, which will benefit the income of blockbuster films.
Strategy:
Buy-in Price: $8.43,Target Price: $9.60,Cut Loss Price: $7.85



Vinda International(3331.HK) - The costs pressure is significant, sales performance remains resilience

Vinda is a leading hygiene company in Asia, with core business segments including tissue, incontinence care, feminine care, baby care and professional hygiene solution under key brands Vinda, Tempo, Tork, TENA, Dr. P, Libresse, Libero and Drypers.

The cost of raw material rises and fx fluctuations, the profit margin is under pressure

FY2022, total revenue increased by 4.0% (growth at constant exchange rates: 8.1%) to HK$19,418 million. Net profit declined by 56.9% to HK$706 million while the net profit margin dipped by 5.2ppts from the previous year to 3.6%. Basic earnings per share was 58.7 HK cents (FY2021: 136.5 HK cents), with a final dividend of 30 HK cents per share. Together with the interim dividend, the total dividend per share for the Year will be 40 HK cents (FY2021: 50HK cents).

In 4Q2022, the quarterly revenue was HK$5,364 million, a decrease of 2.2% YoY (growth at constant exchange rates: 6.4%); the net profit was HK$19 million, a decrease of 95.2% YoY, mainly affected by Covid-19 and continuous rise of material costs.

The company's profit margin was negatively impacted by continuous rise of material costs and currency fluctuation. FY2022, gross profit was down by 16.9% to HK$5,483 million, while gross profit margin down by 7.1 ppts to 28.2%. EBITDA was down by 36.1% to HK$2,104 million and the EBITDA margin declined by 6.8 ppts to 10.8%, due to lower gross margin in the year. Total foreign exchange loss amounted to HK$65.2 million (FY2021: HK$27.5 million gain). However, total sales & administrative costs as a percentage of revenue edged down by 0.4 ppt to 24.5%.

In terms of business segments, revenue from tissue category amounted to HK$16,103 million, which delivered a yoy increase of 3.9% or an organic sales growth of 7.8%, representing 83% of the total revenue (FY2021: 83%). Although better pricing, better mix, and better efficiencies during the year partially offset significant increase in input cost, gross margin and segment result margin of the tissue segment dropped by 7.9 ppts and 7.2 ppts to 27.5% and 5.2%, respectively. Revenue from the personal care category increased by 4.4% to HK$3,314 million, which delivered an organic sales growth1 of 9.6% and representing 17% of the company's total revenue (FY2021: 17%) with gross margin and segment result margin of 31.7% and 2.0%, respectively. Traditional channels, key accounts managed supermarkets and hypermarkets, B2B corporate customers and e-commerce platforms accounted for 24%, 21%, 11% and 44% of revenue by sales channels, respectively. The changing consumer behavior from offline to online accelerated further and e-commerce has been the dominant sales channel with an organic growth of 16.7% year-on-year.

In terms of capacity planning, the annualized designed capacity of the tissue manufacturing facilities was 1,390,000 tons at the end of the Year, including the capacity expansion of tissue production in South and East China which was to fulfil the growing market demand. In addition, Zhejiang's new plant has been put into operation in the second half of 2022, and will further improve the papermaking capacity in 2023. In terms of personal care equipment, the new headquarters of Southeast Asia in Malaysia, equipped with production facilities, warehousing and distribution equipment and modern R & D centers, it has been operated according to the plan (the first phase was put into operation in December 2022). The remaining domestic personal care facilities are located in East China, Central China and Taiwan.

The macroeconomic fluctuations last year led to an unprecedented increase in the cost of raw materials. Observing the recent changes in the market, after the Spring Festival holiday, the price of wood pulp has begun to be reduced. However, in terms of supply, the import volume of piles of piles in 2022 decreased yoy. This has made the domestic supply tightening still exists, resulting the price of wood pulp may support in the high level.

Company valuation

4Q2022 results may be the bottom, and the overall sales performance is still resilience. FY2023 expected to have a more obvious recovery. However, in the short term, it still depends on the price of raw materials (the price of wood pulp is still at a high level). Thus, we expect FY2023E-FY2024E EPS to HK$73.6 cents (vs HKD$1.32 in Aug-2023 report) and HKD$94.1 cent respectively, with TP HKD$14.10, implies a FY2023E P/E of 19.1x, in line with its 5-years average +1SD. Our investment rating is “Sell”.

Risk factors

1) wood pulp prices drop slower than expected; 2) Large fluctuations in RMB; 3) Economic recovery momentum slower than expected, consumer confidence weakens further; and 4) Industry competition is intense than expected.

Financial

Click Here for PDF format...




Recommendation on 21-3-2023
RecommendationSell
Price on Recommendation Date$ 21.750
Suggested purchase priceN/A
Target Price$ 14.100
Writer Info
Eric Li
(Research Analyst)
Tel: (+852 2277 6516)
Email:
erichyli@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2023 Phillip Securities (HK) Ltd. All Rights Reserved.